10月8日，英派药业-B盘中下跌8.07%，报13.32港元，成交额2707.82万港元。
尽管公司核心产品塞纳帕利近期获得欧洲药品管理局人用药品委员会积极意见，且该药已在国内纳入医保并实现快速放量，但股价在连续上涨后出现明显获利回吐压力。此前塞纳帕利国际化里程碑落地叠加港股通纳入，推动股价阶段性走强，部分资金选择在利好兑现后锁定收益。
公司是一家处于商业化阶段的生物技术企业，核心产品塞纳帕利已在中国获批用于卵巢癌一线维持治疗，并持续推进欧洲等海外市场布局。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.